TP53 and ovarian carcinoma: Finally, through the implementation of the indirect co-immunoprecipitation analyses, p53 was not co-immunoprecipitated with mortalin from SHetA2-treated A2780 ovarian cancer cell lysates confirming the ability of SHetA2 to disrupt the interaction of mortalin and p53.